Both compounds are studied in relation to the growth hormone axis, and both show up constantly in the same conversations — but they work through different receptors entirely. Here's how they actually compare.
Ipamorelin is a ghrelin-receptor agonist (a GHRP) — a five-amino-acid peptide that prompts the pituitary to release growth hormone by mimicking the body's hunger-signaling hormone. Tesamorelin is a GHRH analog — a much larger, 44-amino-acid peptide that works further upstream, on the same receptor that native growth hormone releasing hormone acts on. They're often discussed together not because they compete, but because they're frequently studied in combination, acting on two different points of the same signaling pathway.
| Property | Ipamorelin | Tesamorelin |
|---|---|---|
| Chain length | 5 amino acids | 44 amino acids |
| Receptor target | Ghrelin receptor (GHS-R) | GHRH receptor |
| Compound class | Growth hormone releasing peptide (GHRP) | GHRH analog |
| Regulatory status | Not approved as a pharmaceutical | Approved (as Egrifta) for a specific clinical indication |
| Distinguishing research theme | Comparatively selective GH release with less cortisol/prolactin effect than older GHRPs | Sustained GH/IGF-1 elevation and visceral fat research |
GHRH analogs like tesamorelin and GHRPs like ipamorelin act on different receptors that both feed into growth hormone release, which is why the literature frequently pairs a GHRH analog with a GHRP rather than treating them as substitutes for one another. The research rationale is that GHRH analogs increase the amount of growth hormone the pituitary is primed to release, while GHRPs trigger the release itself — two levers on the same system rather than duplicate mechanisms. This is the same logic behind the more commonly referenced pairing of CJC-1295 (another GHRH analog) with ipamorelin — see the CJC-1295 entry for more on that combination.
Tesamorelin has a meaningfully different evidence base than ipamorelin: because it was developed into an approved pharmaceutical for HIV-associated lipodystrophy, there's a body of human clinical trial data behind it that most compounds in this library simply don't have. Ipamorelin's literature, by contrast, is almost entirely preclinical — cell-receptor binding assays and animal studies focused on characterizing its selectivity relative to older-generation GHRPs.
Important distinction: tesamorelin's approved-indication data applies to the branded pharmaceutical formulation and studied clinical population — it does not extend to research-grade material used outside that regulated context. Neither compound's research literature should be read as guidance for any use outside a laboratory research setting.
For the full profile on each compound, see the Ipamorelin and Tesamorelin library entries, or the Science Hub for how growth hormone secretagogues are classified as a category.